Molecular Cancer Therapeutics CTRC-AACR San Antonio Breast Cancer Symposium
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ramos-Nino, M. E.
Right arrow Articles by Mossman, B. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ramos-Nino, M. E.
Right arrow Articles by Mossman, B. T.
Mol Cancer Ther. 2005;4:835-842
© 2005 American Association for Cancer Research

Human mesothelioma cells exhibit tumor cell–specific differences in phosphatidylinositol 3-kinase/AKT activity that predict the efficacy of Onconase

Maria E. Ramos-Nino1, Giovina Vianale2, Tara Sabo-Attwood1, Luciano Mutti3, Camilo Porta4, Nicholas Heintz1 and Brooke T. Mossman1

1 Department of Pathology, University of Vermont College of Medicine, Burlington, Vermont; 2 Department of Oncology and Neuroscience, Sections of Clinical and General Pathology, G. D'Annunzio University, Chieti, Italy; 3 Health Authority 11, Piemonte-IRRCS S. Maugeri Foundation; and 4 Matteo University Hospital, Pavia, Italy

Requests for reprints: Brooke T. Mossman, Department of Pathology, College of Medicine, University of Vermont College of Medicine, 89 Beaumont Avenue, HSRF 215, Burlington, VT 05405. Phone: 802-656-0382; Fax: 802-656-8892. E-mail: Brooke.Mossman{at}uvm.edu

Malignant mesothelioma is an aggressive cancer with no known cure, which has become a therapeutic challenge. Onconase is one of few chemotherapeutic agents that have been studied in patients with malignant mesothelioma that has the advantage of low toxicity and limited side effects. Here, we evaluate the effect of Onconase on killing of malignant mesothelioma cells and how the phosphatidylinositol 3-kinase/AKT (PI3-K/AKT) survival pathway influences this effect. Our results show that Onconase induces apoptosis in malignant mesothelioma cell lines and that this effect is tumor cell specific. Malignant mesothelioma cell lines with the highest AKT activation, which correlated with the presence of the SV40 large and small T antigen (SV40+), were the most resistant to the drug. Finally, a cooperative effect was observed between small molecule inhibitors of PI3-K and Onconase in the killing of malignant mesothelioma cells. Our results suggest that kinase screening of individual malignant mesotheliomas for endogenous levels of activated PI3-K/AKT may be predictive of the efficacy of Onconase and possibly other chemotherapeutic agents.


Key Words: AKT • PI3-K • chemotherapy • Onconase • survival • resistance • SV40

Grant support: NIH grant R01s ES/HL02913 (B.T. Mossman), K01 CA104159-01 (M.E. Ramos-Nino), and the Italian Association of Cancer Research (G. Vianale).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

5 Altamore DA, You H, Xiao G, et al. Human and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth. Oncogene. In Press 2005.

Received 9/13/04; revised 1/22/05; accepted 3/ 2/05.




This article has been cited by other articles:


Home page
Molecular Cancer TherapeuticsHome page
M. E. Ramos-Nino and B. Littenberg
A novel combination: ranpirnase and rosiglitazone induce a synergistic apoptotic effect by down-regulating Fra-1 and Survivin in cancer cells
Mol. Cancer Ther., July 1, 2008; 7(7): 1871 - 1879.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Cell Mol. Bio.Home page
C. B. Manning, T. Sabo-Attwood, R. F. Robledo, M. B. MacPherson, M. Rincon, P. Vacek, D. Hemenway, D. J. Taatjes, P. J. Lee, and B. T. Mossman
Targeting the MEK1 Cascade in Lung Epithelium Inhibits Proliferation and Fibrogenesis by Asbestos
Am. J. Respir. Cell Mol. Biol., May 1, 2008; 38(5): 618 - 626.
[Abstract] [Full Text] [PDF]


Home page
ThoraxHome page
H Kothmaier, F Quehenberger, I Halbwedl, P Morbini, F Demirag, H Zeren, C E Comin, B Murer, P T Cagle, R Attanoos, et al.
EGFR and PDGFR differentially promote growth in malignant epithelioid mesothelioma of short and long term survivors
Thorax, April 1, 2008; 63(4): 345 - 351.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. R. Pietruska and A. B. Kane
SV40 Oncoproteins Enhance Asbestos-Induced DNA Double-Strand Breaks and Abrogate Senescence in Murine Mesothelial Cells
Cancer Res., April 15, 2007; 67(8): 3637 - 3645.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Cell Mol. Bio.Home page
S. R. Blumen, K. Cheng, M. E. Ramos-Nino, D. J. Taatjes, D. J. Weiss, C. C. Landry, and B. T. Mossman
Unique Uptake of Acid-Prepared Mesoporous Spheres by Lung Epithelial and Mesothelioma Cells
Am. J. Respir. Cell Mol. Biol., March 1, 2007; 36(3): 333 - 342.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Cell Mol. Bio.Home page
K.-U. Kim, S. M. Wilson, K. S. Abayasiriwardana, R. Collins, L. Fjellbirkeland, Z. Xu, D. M. Jablons, S. L. Nishimura, and V. C. Broaddus
A Novel In Vitro Model of Human Mesothelioma for Studying Tumor Biology and Apoptotic Resistance
Am. J. Respir. Cell Mol. Biol., December 1, 2005; 33(6): 541 - 548.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2005 by the American Association for Cancer Research.